Drug pipeline
Full profile accessExplore the programs pursuing this target and their development progress.
- Drug candidates
- Developers
- Development stage
Target intelligence / Profile preview
RNU6-714P represents a pseudogene related to U6 small nuclear RNA (snRNA). U6 snRNA is a highly conserved non-coding RNA that is a key component of the spliceosome, facilitating pre-mRNA splicing within the nucleus. The U6 snRNA gene family includes numerous pseudogenes in vertebrate genomes, such as RNU6-714P, which are considered non-functional copies arising from ancestral gene duplication or retrotransposition events. Pseudogenes like RNU6-714P are not translated into proteins and, in most cases, do not produce functional RNA products[2][3]. While a few pseudogenes elsewhere in the genome can sometimes have regulatory non-coding RNA functions (e.g., competing endogenous RNAs), there is no evidence for RNU6-714P involvement in disease, regulatory function, or pharmacological targeting[2][3][4]. RNU6-714P is annotated in genomic databases, but is not species-specific nor functionally characterized[2]. U6 small nuclear RNA itself is essential for spliceosome function, mediating the removal of introns from pre-mRNA, but this is not true for its pseudogenes[1][3][5]. Vertebrate genomes contain multiple U6 pseudogenes as evolutionary "backups," yet most lack functional roles[3]. There are no drugs known to act on U6 pseudogenes, nor are they used as biomarkers or involved in any known mechanisms of therapeutic action[2][3][4]. No safety concerns or therapeutic challenges have been reported regarding RNU6-714P. RNU6-714P is a pseudogene version of U6 small nuclear RNA and is not itself a molecular target or associated with diseases, drugs, or biomarkers. Its annotation as a "pseudogene" (by definition) indicates a lack of biological activity or clinical relevance[2][3].
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Explore the programs pursuing this target and their development progress.
Follow the clinical studies evaluating therapies directed at this target.
Compare approaches across drug candidates, modalities, and indications.
Investigate the research and source evidence behind target biology and development.
Explore patent activity around therapies and technologies addressing this target.
Connect target biology, drug development, and emerging evidence in your research.
See how Gosset can support your research on RNA, U6 small nuclear 714, pseudogene (RNU6-714P).